The Future

Collecting cells at a young age
enables the production of
high-quality iPS (stem) cells.

Regenerative medicine that
avoids the risk of rejection by using
your own cells.

Collaboration
Personal iPS is being marketed overseas through Japan Medical & Health Tourism Center (JMHC), a medical coordination division established by JTB Co. In Japan, applications can now be made through JTB in addition to REPROCELL, Inc. as in the past.



Features
Features of Pesonal iPS


Development of iPS cells for various
types of regenerative medicine
In Japan, Europe and the United States, clinical trials (includes administration to humans) using iPS cells have begun. A future in which diseases that were once untreatable can be cured by regenerative medicine using iPS cells is beginning to become a reality.


Avoid risk of rejection
Transplantation or treatment using the individual’s own cells (autologous transplantation) is less likely to cause rejection.
It is believed that the availability of autologous transplantation therapy will eliminate the need to search for donors for various diseases and treatments can be initiated quickly.


Derivation of iPS cells from unneeded
teeth or urine
Our technology makes the derivation of iPS cells easy and suitable for anyone. Cells are collected from unneeded teeth (e.g. lost babey teeth) or urine.
Note: Tooth extraction for the sole purpose of producing iPS cells is not available (performed).


Leading company of iPS cells
Since our establishment in 2003, we have been engaged in cutting-edge research and development of iPS cells. Our cell culture media has been used in the research of Professor Yamanaka, a Nobel Prize winner. Our products are highly trusted both in Japan and overseas and have been cited in more than 6,000 papers to date. (As of November 2020)